NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials BELFAST, Northern Ireland, May 28,...
Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials BELFAST, Northern Ireland, May 28,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.